Vensica Medical Receives FDA IND Clearance for Phase 2 Study of ViXe Delivery System
Vensica Medical has received FDA clearance for its IND application to start a Phase 2 clinical trial evaluating ViXe, a needle-free delivery system for Xeomin, aimed at treating overactive bladder.
NEW YORK–(BUSINESS WIRE)–Vensica Medical, a clinical-stage company developing needle-free therapeutic delivery solutions for urologic diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application to initiate a Phase 2 clinical trial of ViXe. The study will evaluate the Vibe® ultrasound-based, needle-free drug delivery system in combination with Xeomin® (incobotulinumtoxinA) for the treatment of overactive bladde